This powerful combination of a quarterly beat and a significantly upgraded outlook sent Vodafone shares surging 4.67% on Monday . Both Bloomberg and Reuters cited Vodafone's Q1 beat and upgraded outlook as a major stock mover on the day
.
AstraZeneca reported its H1 and Q2 2026 results, which comfortably beat profit expectations. Key figures from the report include:
Crucially, the company reaffirmed its long-term ambition to reach $80 billion in total revenue by 2030, a goal supported by its strong pipeline in oncology, rare disease, and weight-loss treatments . The results were well-received, with AstraZeneca shares edging modestly higher on Monday following the release
.
While Vodafone and AstraZeneca drove stock-specific gains, the broader European rally was fueled by a significant macro event. Over the weekend, the US paused its air campaign against Iran for a second consecutive night, and Iran refrained from further strikes, triggering a powerful risk-on rally across equity markets . A senior Iranian official told Reuters that Iran would halt attacks if the US did the same
.
This geopolitical de-escalation had an immediate and dramatic effect on oil prices:
With Monday's rally behind them, markets are now laser-focused on a dense US calendar, where four "Magnificent Seven" earnings reports and a Federal Reserve interest rate decision are all compressed into the same week .
The results from four of the world's largest tech companies are expected to be the dominant market driver for the rest of the week, coming on the heels of Alphabet's disappointing report . Investors are expected to scrutinize AI-related capital expenditure, cloud revenue growth, and overall margin resilience
.
The Federal Open Market Committee (FOMC) is set to announce its latest monetary policy decision, which will be a major focus for global markets.
Despite the relief rally, significant risks remain on the horizon that could alter the market's trajectory.
In short, Monday's European rally was a powerful "double boost"—strong company results from Vodafone and AstraZeneca layered on top of a geopolitical relief rally driven by falling oil prices. However, the market's attention has already pivoted to what matters most for the rest of the week: the outcome of the Fed's policy meeting and the next wave of earnings from Big Tech.